Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Heron Therapeutics ( (HRTX) ) has issued an update.
On April 3, 2026, Heron Therapeutics amended and restated Chief Executive Officer Craig Collard’s employment agreement, significantly revising severance, bonus, and equity treatment terms tied to terminations and change-in-control events. The amendment introduces larger cash severance, extended COBRA coverage, and broad-based equity acceleration for Collard in both standard and change-in-control termination scenarios, while tightening non-compete, non-solicit, and confidentiality obligations and shifting governing law and employment location to North Carolina.
On the same date, Heron also executed amended and restated management retention agreements for its CFO, CDO, and COO, enhancing cash and equity severance protections, including double-trigger change-in-control benefits and extended health coverage. These revised agreements add robust protective covenants, clarify performance-based vesting mechanics, and remove renewal terms so the contracts remain in force until amended, underscoring the company’s focus on leadership retention and deal-readiness in potential strategic transactions.
The most recent analyst rating on (HRTX) stock is a Hold with a $0.81 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
The score is held down primarily by balance-sheet leverage and ongoing cash burn despite major profitability improvement, alongside a clearly bearish technical trend. Offsetting these, management’s 2026 guidance and Q4 Acute Care sales acceleration support a better forward outlook, but valuation remains difficult to assess given negative earnings and no dividend.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments, typically using proprietary drug delivery technologies, to address unmet medical needs. The company operates in the U.S. healthcare sector and competes in markets where executive continuity and retention are strategically important, particularly around potential change-in-control transactions.
Average Trading Volume: 1,794,663
Technical Sentiment Signal: Sell
Current Market Cap: $150.7M
For detailed information about HRTX stock, go to TipRanks’ Stock Analysis page.